IQVIA Holdings Inc. announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories. The acquisition includes five sites specializing in in vitro drug discovery services, supported by over 20 years of scientific data, creating an industry-leading integrated drug discovery platform.
Following the release of its IQVIA 2025 earnings, the life sciences leader reported a record-breaking $32.7 billion backlog and a double-digit revenue surge in the fourth quarter, outperforming Wall Street expectations. As the company transitions into 2026, it is doubling down on a specialized Healthcare-grade AI strategy—anchored by its proprietary Med-R1 reasoning model and strategic cloud partnerships with NVIDIA and AWS—to safeguard its core business against industry-wide disruption.
For the third quarter that concluded on September 30, 2025, IQVIA Holdings Inc. (NYSE: IQV) posted solid financial results. The company’s profit and revenue were [Read More…]
IQVIA reported $3.829 billion in total revenue for the first quarter that ended on March 31, 2025, a 2.5% increase over the same period in 2024.
